- Home
- AR vs JAZZ Comparison
AR vs JAZZ Comparison
Compare AR & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AR | JAZZ |
|---|---|---|
| Founded | 2002 | 2003 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.9B | 10.4B |
| IPO Year | 2013 | 2007 |
Fundamental Metrics
Financial Performance| Metric | AR | JAZZ |
|---|---|---|
| Price | $34.76 | $166.31 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 16 |
| Target Price | $44.53 | ★ $207.19 |
| AVG Volume (30 Days) | ★ 6.4M | 774.0K |
| Earning Date | 02-11-2026 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1027.78 | N/A |
| EPS | ★ 2.03 | N/A |
| Revenue | ★ $5,139,510,000.00 | $4,157,832,999.00 |
| Revenue This Year | $21.00 | $6.19 |
| Revenue Next Year | $6.88 | $6.46 |
| P/E Ratio | $17.12 | ★ N/A |
| Revenue Growth | ★ 19.59 | 4.14 |
| 52 Week Low | $29.10 | $95.49 |
| 52 Week High | $44.02 | $182.99 |
Technical Indicators
Market Signals| Indicator | AR | JAZZ |
|---|---|---|
| Relative Strength Index (RSI) | 53.22 | 50.01 |
| Support Level | $33.03 | $161.38 |
| Resistance Level | $35.64 | $167.73 |
| Average True Range (ATR) | 1.40 | 4.02 |
| MACD | 0.02 | -0.02 |
| Stochastic Oscillator | 49.86 | 58.07 |
Price Performance
Historical ComparisonAbout AR Antero Resources Corporation
Antero Resources, based in Denver, explores for and produces natural gas and natural gas liquids in the United States and Canada. At the end of 2024, the company reported proven reserves of 17.9 trillion cubic feet of natural gas equivalent. Production averaged approximately 3,424 million cubic feet of equivalent a day in 2024 at a ratio of 35% liquids and 65% natural gas.
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.